reconstitute cagrilintide 10mg (10mg vials) CAGRILINTIDE PEPTIDE 5MG/10MG VIAL –

In REDEFINE 1 (NEJM 2025, n=3,417, 68 weeks), cagrilintide monotherapy at 2.4 mg produced 11.8% mean body-weight reduction versus 2.3% with placebo

Research-Use Dosing Conventions (Not a Recommendation) This section describes the dose ranges used inside clinical trials and laboratory research settings only

Novo Nordisk developed it as a long-acting version of the naturally occurring hormone, engineered with specific amino acid substitutions that extend its duration of action from minutes to days

However, it's essential to consult a veterinarian before administering BPC 157 to ensure it is appropriate for your dog's specific health needs and conditions